Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teh-Ia Huo

Showing results (21-30 of 229) with videos related to

Pageof 23
Sort By:
The American Journal of Gastroenterology|June 19, 2007
The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential surveyTeh-Ia Huo, Han-Chieh Lin, Cheng-Yuan Hsia, et al.
Annals of Surgical Oncology|June 7, 2014
Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteriaPo-Hong Liu, Yun-Hsuan Lee, Chia-Yang Hsu, et al.
Plos One|December 13, 2018
Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI scoreYun-Cheng Hsieh, Kuei-Chuan Lee, Ying-Wen Wang, et al.
Cancer|May 19, 2006
The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapyTeh-Ia Huo, Han-Chieh Lin, Yi-Hsiang Huang, et al.
Scandinavian Journal of Gastroenterology|April 25, 2007
Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias?Teh-Ia Huo, Yi-Hsiang Huang, Jen-Huei Chiang, et al.
Plos One|October 15, 2013
CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot studyI-Cheng Lee, Yi-Hsiang Huang, Chien-Wei Su, et al.
International Journal of Cancer|June 11, 2013
Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatmentsI-Cheng Lee, Yi-Hsiang Huang, Gar-Yang Chau, et al.
Journal of Clinical Gastroenterology|August 19, 2006
Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: incidence and risk factor analysisTeh-Ia Huo, Yi-Hsiang Huang, Hui-Chun Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2020
Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapyChi-Jung Wu, Gar-Yang Chau, I-Cheng Lee, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 20, 2020
Metavir Fibrosis Stage in Hepatitis C-Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve ModelsShu-Yein Ho, Lei-Chi Wang, Chia-Yang Hsu, et al.
Pageof 23

Showing results (21-30 of 229) with videos related to

Sort By:
Pageof 23
The American Journal of Gastroenterology|June 19, 2007
The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential surveyTeh-Ia Huo, Han-Chieh Lin, Cheng-Yuan Hsia, et al.
Annals of Surgical Oncology|June 7, 2014
Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteriaPo-Hong Liu, Yun-Hsuan Lee, Chia-Yang Hsu, et al.
Plos One|December 13, 2018
Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI scoreYun-Cheng Hsieh, Kuei-Chuan Lee, Ying-Wen Wang, et al.
Cancer|May 19, 2006
The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapyTeh-Ia Huo, Han-Chieh Lin, Yi-Hsiang Huang, et al.
Scandinavian Journal of Gastroenterology|April 25, 2007
Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias?Teh-Ia Huo, Yi-Hsiang Huang, Jen-Huei Chiang, et al.
Plos One|October 15, 2013
CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot studyI-Cheng Lee, Yi-Hsiang Huang, Chien-Wei Su, et al.
International Journal of Cancer|June 11, 2013
Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatmentsI-Cheng Lee, Yi-Hsiang Huang, Gar-Yang Chau, et al.
Journal of Clinical Gastroenterology|August 19, 2006
Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: incidence and risk factor analysisTeh-Ia Huo, Yi-Hsiang Huang, Hui-Chun Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2020
Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapyChi-Jung Wu, Gar-Yang Chau, I-Cheng Lee, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 20, 2020
Metavir Fibrosis Stage in Hepatitis C-Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve ModelsShu-Yein Ho, Lei-Chi Wang, Chia-Yang Hsu, et al.
Pageof 23